Elamipretide (research), Bendavia, MTP-131
Evidence Grade C — Moderate human evidence. 263 published studies, 104 human. 0 registered clinical trials.
SS-31 is the research name for elamipretide, a peptide that targets mitochondrial membranes. A pharmaceutical version (Forzinity) has received regulatory authorisation for Barth syndrome, a rare genetic mitochondrial disease. This entry covers SS-31 in its broader research and unregulated context — available through unregulated channels for purposes beyond the narrow authorised indication.
263 published studies: 104 human, 111 animal, 50 in-vitro, 36 reviews
Elamipretide has received FDA approval for Barth syndrome under the brand name Forzinity, based on open-label extension data showing improved walking distance and muscle strength. A larger Phase III trial in primary mitochondrial myopathy (218 patients) did not meet its primary endpoint, and the drug was not approved for that broader indication.
SS-31 is available through unregulated channels for purposes beyond the approved Barth syndrome indication. The failed Phase III trial in primary mitochondrial myopathy demonstrates that mitochondrial targeting does not guarantee clinical benefit across all mitochondrial conditions. Products from unregulated sources lack pharmaceutical quality assurance.
Elamipretide binds to cardiolipin, a unique phospholipid in the inner mitochondrial membrane, stabilising the membrane structure that is essential for energy production. This mechanism is well characterised from the approved product's development. The drug restores mitochondrial function at its structural foundation rather than targeting a specific enzyme.
Research suggests the pharmaceutical version's approval for Barth syndrome validates the mitochondria-targeting mechanism, but a larger Phase III trial in primary mitochondrial myopathy (218 patients) failed its primary endpoint — demonstrating that mitochondrial targeting does not automatically translate to benefit across all mitochondrial conditions. Every randomised placebo-controlled portion of every major elamipretide trial failed primary endpoints; positive signals came from open-label extensions and post-hoc analyses. The Barth syndrome approval rests on a surrogate endpoint in just 8 patients who completed the open-label extension. Products from unregulated sources lack pharmaceutical quality assurance and are used for indications without clinical trial support.
No trials registered on ClinicalTrials.gov for this compound.
FDA ORIG 1
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
